English

RLS GLOBAL AB (publ) YEAR-END REPORT 2020

Report this content

OCTOBER 1st–DECEMBER 31st

  • Net sales amounted to KSEK 139 (KSEK 54)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -7,2 (MSEK -8,9)
  • Earning per share before dilution at SEK -0,11 (SEK -0,15)
  • Cash flow from operating activities amounted to MSEK -7,0 (MSEK -5,7)
  • Liquid assets at the end of the period MSEK 18,9 (MSEK 41,7)
  • Equity ratio was 88 % (90 %)
     

JANUARY 1st–DECEMBER 31st

  • Net sales amounted to KSEK 2,043 (KSEK 1,023)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -22,3 (MSEK -26,7)
  • Earning per share before dilution at SEK -0,34 (SEK-0,44)
  • Cash flow from operating activities amounted to MSEK -22,2 (MSEK-24,9)
  • Liquid assets at the end of the period MSEK 18,9 (MSEK 41,7)
  • Equity ratio was 88 % (90 %)
     

SUMMARY OF EVENTS DURING FOURTH QUARTER

  • Continued focus on future regional/global cooperation.
  • RLS participated in EWMA, the European Wound Conference which this year was digital. Docent Jan Apelqvist presented an abstract from the ChloraSolv01 study.
  • A pre-study regarding automatic production has been conducted during fall.
  • New exciting results from tests performed in Lund.
     

SUMMARY OF EVENTS DURING THE YEAR

SUMMARY OF EVENTS DURING Q1

  • Redeye was appointed new Certified Adviser.
  • The immaterial rights regarding PeriSolv was sold to Regident AG.
  • RLS signed a contract with Region Kalmar län.
     

SUMMARY OF EVENTS DURING Q2

  • RLS signed contracts with Region Stockholm/Gotland.
  • Increased use of ChloraSolv in Region Kalmar län.
     

SUMMARY OF EVENTS DURING Q3

  • ChloraSolv approved in Canada.
  • RLS signed contract with Region Skåne.
  • Recurrent sales of ChloraSolv.
     

SUMMARY OF EVENTS AFTER FOURTH QUARTER

  • RLS Global was audited by Eurofins and Lloyds (notified bodies) with very good result.
     

COVID-19

  • In the current situation, the Board has considered the impact of different possible future covid-19 related scenarios.
  • Since the healthcare sector is so extremely strained under the prevailing circumstances, all processes take longer which affects our market penetration and other activities, resulting in RLS focusing even more on R&D projects.
     

TRADING PLACE AND CERTIFIED ADVISER
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. phone: +46 8 121 576 90, email: certifiedadviser@redeye.se.
During the period 2012–2017, the company was listed on Aktietorget.

The Year-end report is enclosed and is also available at:
https://rls.global/wp-content/uploads/2021/02/RLS_Global_Q4_2020_EN.pdf

PUBLICATION
This information was submitted for publication through the agency of the above contact person, at 09.00 CET on February 10th, 2021.

CONTACT INFORMATION
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Read more at www.rls.global

Tags:

RLS RLS Global

Subscribe

Documents & Links